Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Crispr Technology: A Versatile Tool to Model, Screen, and Reverse Drug Resistance in Cancer Publisher Pubmed



Shiranibidabadi S1 ; Tabatabaee A2 ; Tavazohi N3 ; Hariri A1 ; Aref AR4, 5 ; Zarrabi A6 ; Casarcia N7 ; Bishayee A7 ; Mirian M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, 8174673461, Iran
  2. 2. Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, 8174673461, Iran
  3. 3. Novel Drug Delivery Systems Research Centre, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, 8174673461, Iran
  4. 4. Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, 02215, MA, United States
  5. 5. Translational Sciences, Xsphera Biosciences Inc, Boston, 02215, MA, United States
  6. 6. Department of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Istinye University, Istanbul, 34396, Turkey
  7. 7. College of Osteopathic Medicine, Lake Erie College of Osteopathic Medicine, Bradenton, 34211, FL, United States

Source: European Journal of Cell Biology Published:2023


Abstract

Background: Drug resistance is a serious challenge in cancer treatment that can render chemotherapy a failure. Understanding the mechanisms behind drug resistance and developing novel therapeutic approaches are cardinal steps in overcoming this issue. Clustered regularly interspaced short palindrome repeats (CRISPR) gene-editing technology has proven to be a useful tool to study cancer drug resistance mechanisms and target the responsible genes. In this review, we evaluated original research studies that used the CRISPR tool in three areas related to drug resistance, namely screening resistance-related genes, generating modified models of resistant cells and animals, and removing resistance by genetic manipulation. We reported the targeted genes, study models, and drug groups in these studies. In addition to discussing different applications of CRISPR technology in cancer drug resistance, we analyzed drug resistance mechanisms and provided examples of CRISPR's role in studying them. Although CRISPR is a powerful tool for examining drug resistance and sensitizing resistant cells to chemotherapy, more studies are required to overcome its disadvantages, such as off-target effects, immunotoxicity, and inefficient delivery of CRISPR/cas9 into the cells. © 2023 The Authors
Related Docs
View other Related Docs
1. Fabrication and Evaluation of a Dual-Targeting Nanoparticle Mediated Crispr/Cas9 Delivery to Combat Drug Resistance in Breast Cancer Cells, Journal of Drug Delivery Science and Technology (2023)
2. Gene Network Analysis of Oxaliplatin-Resistant Colorectal Cancer to Target a Crucial Gene Using Chitosan/Hyaluronic Acid/Protamine Polyplexes Containing Crispr-Cas9, Biochimica et Biophysica Acta - General Subjects (2023)
3. Molecular Mechanisms of Drug Resistance in Ovarian Cancer, Journal of Cellular Physiology (2018)
4. Crispr/Cas9, a New Approach to Successful Knockdown of Abcb1/P-Glycoprotein and Reversal of Chemosensitivity in Human Epithelial Ovarian Cancer Cell Line, Iranian Journal of Basic Medical Sciences (2018)
5. Microrna-219 in the Central Nervous System: A Potential Theranostic Approach, Research in Pharmaceutical Sciences (2024)
6. The Emerging Role of Circular Rnas in Cisplatin Resistance in Ovarian Cancer: From Molecular Mechanism to Future Potential, Non-coding RNA Research (2024)
7. Gene-Knocked Out Chimeric Antigen Receptor (Car) T Cells: Tuning up for the Next Generation Cancer Immunotherapy, Cancer Letters (2018)
8. Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin, Frontiers in Oncology (2021)
Experts (# of related papers)
View all Related Experts
Ilnaz Rahimmanesh (4)
Mina Mirian (4)
Other Related Docs
9. Micrornas, Long Non-Coding Rnas, and Circular Rnas and Gynecological Cancers: Focus on Metastasis, Frontiers in Oncology (2023)
10. Effects of Abcg2 C421a and Abcg2 G34a Genetic Polymorphisms on Clinical Outcome and Response to Imatinib Mesylate, in Iranian Chronic Myeloid Leukemia Patients, Egyptian Journal of Medical Human Genetics (2023)
11. Genetic Advancements in Breast Cancer Treatment: A Review, Discover Oncology (2025)
12. Gene Editing-Based Technologies for Beta-Hemoglobinopathies Treatment, Biology (2022)
13. Lncarod Promotes the Proliferation and Migration of Gastric Cancer: A Bioinformatics Analysis and Experimental Validation, Functional and Integrative Genomics (2023)
14. Advances in Aptamer-Based Drug Delivery Vehicles for Cancer Therapy, Biomaterials Advances (2022)
15. Exploring Advanced Crispr Delivery Technologies for Therapeutic Genome Editing, Small Science (2024)
16. Crispr–Cas9 in Genome Editing: Its Function and Medical Applications, Journal of Cellular Physiology (2019)
17. Harnessing Crispr/Cas9 Technology in Cardiovascular Disease, Trends in Cardiovascular Medicine (2020)
18. Exploring Metal-Organic Frameworks in Gene Delivery: From Prostate to Lung Therapeutics, Applied Materials Today (2024)
19. Non-Coding Rnas in Leukemia Drug Resistance: New Perspectives on Molecular Mechanisms and Signaling Pathways, Annals of Hematology (2024)
20. Stat3 As a Newly Emerging Target in Colorectal Cancer Therapy: Tumorigenesis, Therapy Response, and Pharmacological/Nanoplatform Strategies, Environmental Research (2023)
21. Epigenetic Regulation of Autophagy in Gastrointestinal Cancers, Biochimica et Biophysica Acta - Molecular Basis of Disease (2022)
22. Development of Α4 Integrin Dna Aptamer As a Potential Therapeutic Tool for Multiple Sclerosis, Journal of Cellular Biochemistry (2019)
23. Methotrexate-Conjugated to Polymer Quantum Dot for Cytotoxicity Effect Improved Against Mcf-7 and Hela Cells, Medicinal Chemistry Research (2018)